BWIN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Baldwin Insurance Group, Inc (BWIN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, has mixed analyst sentiment, and faces near-term headwinds. While hedge funds are buying, insider selling and weak financial performance metrics suggest caution. Given the investor's preference for long-term growth and the absence of strong buy signals, holding off on buying is recommended.
The MACD is slightly positive but contracting, RSI is neutral at 50.687, and moving averages are converging, indicating no strong trend. Key support is at 20.985, and resistance is at 22.916. The stock closed at 21.94, showing a -3.60% decline in regular trading, with a slight pre-market recovery of 0.66%. Overall, the technical indicators suggest a lack of clear upward momentum.
Hedge funds are significantly increasing their holdings, with a 684.07% increase in buying over the last quarter. Analysts like Raymond James and TD Cowen highlight valuation and potential growth tailwinds from synergies and embedded distribution networks. Recent upgrades and buy ratings suggest some confidence in the long-term growth profile.
Insiders are selling heavily, with a 577.76% increase in selling over the last month. The stock has dropped 23% year-to-date due to AI concerns and near-term organic revenue growth headwinds. Analysts have been lowering price targets, and the stock has a 60% chance of further declines in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased by 84.83% YoY to $95,079,000, but net income remains negative at -$25,861,000, albeit improving by 28.27% YoY. EPS also improved to -0.37, up 12.12% YoY. Despite revenue growth, the company is still unprofitable, and gross margin remains at 0%, indicating operational inefficiencies.
Analyst sentiment is mixed. JPMorgan and Keefe Bruyette have lowered price targets but maintain Neutral and Outperform ratings, respectively. UBS and TD Cowen maintain Buy ratings with higher price targets, while Raymond James upgraded the stock to Strong Buy, citing valuation and growth potential. However, the overall trend shows a reduction in price targets, reflecting cautious optimism.
